{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-23-000163","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.941880+00:00","generated_at":"2026-06-08T06:52:11.642010+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BeiGene Q3 revenue $781M (+102% YoY); net income of $215M vs loss of $558M last year","bullets":["Global product sales up 70% to $595M; BRUKINSA sales $358M (+130%) led by US launch momentum.","Net income $215M vs net loss $558M in Q3 2022; operating loss improved by $304M YoY.","Total revenue $781M (+102%); US revenue $398M, China $288M, Europe $86M.","Gross margin improved to 83.8% from 78.1% on higher-mix BRUKINSA and lower tislelizumab costs.","Cash $3.2B; TEVIMBRA approved in EU, US BLA accepted for ESCC with PDUFA July 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-23-000163","json":"https://secwatch.observer/filing/0001651308-23-000163.json","markdown":"https://secwatch.observer/filing/0001651308-23-000163.md","text":"https://secwatch.observer/filing/0001651308-23-000163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/0001651308-23-000163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/bgne-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:52:11.642010+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1cd52edc242e86563d2ceb3ce70445d89faaed9e","claim":"BeOne Medicines Ltd. reported the three months ended September 30, 2023 results: revenue total revenue of $781 million, net income Net Income ... $215.4 million.","evidence_excerpt":"Report on Form 8-K. --- EX-99.1 (EX-99.1) --- BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates • Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage • Global sales of BRUKINSA","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651308/000165130823000163/0001651308-23-000163-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2023"},{"label":"Revenue","value":"total revenue of $781 million"},{"label":"Net income","value":"Net Income ... $215.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}